alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<partyblock><br><br><div align="center"><b><font size="+1">Holtsville Chiropractic, P.C., as Assignee of Ana Gomez, Respondent, <br><br>against<br><br>AutoOne Insurance Company, Appellant.</font></b></div><br><br><p>Law Office of Jason Tenenbaum, P.C. (Jason Tenenbaum, Esq.), for appellant.Mandell &amp; Santora, for respondent (no brief filed).</p><p>Appeal from an order of the Civil Court of the City of New York, Queens County (Richard G. Latin, J.), entered December 8, 2014. The order, insofar as appealed from as limited by the brief, denied the branches of defendant's motion seeking to compel plaintiff to appear for an examination before trial and to strike the notice of trial.</p><p>ORDERED that the order, insofar as appealed from, is reversed, with $30 costs, the branches of defendant's motion seeking to compel plaintiff to appear for an examination before trial and to strike the notice of trial are granted, and the examination shall be held within 60 days of the date of this decision and order, at such time and place to be specified in a written notice by defendant of not less than 10 days, or at such other time and place as the parties may agree upon.</p><p>In this action by a provider to recover assigned first-party no-fault benefits, insofar as is relevant to this appeal, the Civil Court denied the branches of a motion by defendant seeking to compel plaintiff to appear for an examination before trial and to strike the notice of trial.</p><p>For the reasons stated in <i>S.J. Pahng, M.D., P.C., as Assignee of Jin Hee Ma v AutoOne Ins. Co.</i> (__ Misc 3d ___, 2017 NY Slip Op _____ [appeal No. 2014-2842 Q C], decided herewith), the branch of defendant's motion seeking to compel plaintiff to appear for an examination before trial should have been granted; therefore, the branch of defendant's motion seeking to strike the notice of trial should also have been granted.</p><p>Accordingly, the order, insofar as appealed from, is reversed and the branches of defendant's motion seeking to compel plaintiff to appear for an examination before trial and to strike the notice of trial are granted.</p><p>PESCE, P.J., ALIOTTA and SOLOMON, JJ., concur.</p><br>ENTER:<br>Paul Kenny<br>Chief Clerk<br>Decision Date: November 03, 2017<br><br><div align="center"><form method="LINK" action="../../slipidx/at_2_idxtable.shtml"><input type="submit" value="Return to Decision List"></form></div></partyblock>
# L_2012164DE.01001801.xml

| 23.6.2012 | DE | Amtsblatt der Europäischen Union | L 164/18 |
| --- | --- | --- | --- |

23.6.2012

DE

Amtsblatt der Europäischen Union

L 164/18

---

Berichtigung der Verordnung (EG) Nr. 300/2008 des Europäischen Parlaments und des Rates vom 11. März 2008 über gemeinsame Vorschriften für die Sicherheit in der Zivilluftfahrt und zur Aufhebung der Verordnung (EG) Nr. 2320/2002

(
  Amtsblatt der Europäischen Union L 97 vom 9. April 2008
  )

Amtsblatt der Europäischen Union L 97 vom 9. April 2008

Im Anhang auf Seite 82, Abschnitt 4.1. „Kontrolle von Fluggästen und Handgepäck“, Nummer 3 Buchstabe b:

anstatt:

| „b) | sie treffen nicht mit anderen kontrollierten abfliegenden Fluggästen zusammen, die dasselbe Luftfahrzeug besteigen, oder” |
| --- | --- |

„b)

sie treffen nicht mit anderen kontrollierten abfliegenden Fluggästen zusammen, die dasselbe Luftfahrzeug besteigen, oder”

muss es heißen:

| „b) | sie treffen nicht mit anderen kontrollierten abfliegenden Fluggästen zusammen, außer denen, die dasselbe Luftfahrzeug besteigen, oder”. |
| --- | --- |

„b)

sie treffen nicht mit anderen kontrollierten abfliegenden Fluggästen zusammen, außer denen, die dasselbe Luftfahrzeug besteigen, oder”.

---
#### Majestic Investors, Ltd., Plaintiff, v Augustine Lopez, Appellant, and 169 North Main Renewal Corp., Respondent, et al., Defendants. (And Other Titles.)

In an action, *inter alia,*to foreclose a mortgage, the appeal is from an order of the Supreme Court, Nassau County (Roberto, J.), dated June 19, 1984, which denied appellant’s motion, among other things, to amend her answer and third-party amended answer.

Order affirmed, with one bill of costs.

The note of issue in this action was filed by appellant in February 1979. The case reached the Day Calendar in October 1979, but was marked off due to the absence of appellant’s former husband, who had died in December 1978. Appellant wife obtained letters of administration in 1981 and thereafter the lawsuit lay dormant until April 1984, when appellant moved, *inter alia,*to amend her answer and third-party amended answer. The moving papers proffered no excuse for the delay of over three years in moving to amend, contained an inadequate affidavit of merits, and failed to demonstrate a lack of prejudice to the other parties *(see, Warner v Kudler,*101 AD2d 886). Mollen, P. J., Rubin, Lawrence and Kunzeman, JJ., concur.
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2374 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 2374

                To suspend temporarily the duty on ESPI.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 16, 2005

 Mrs. Capito introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
                To suspend temporarily the duty on ESPI.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ESPI.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.09.04      2-                  Free         No change        No change        On or before 12/  ''.
                         (isocyanatosulfon                                                  31/2008
                         yl)-benzoic acid,
                         ethyl ester
                         (ESPI) (CAS No.
                         77375-79-2)
                         (provided for in
                         subheading
                         2930.90.29)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of enactment of this Act.
                                 <all>
```
EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                                   AS ADDED BY
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Equitex, Inc. (the "Company") on Form
10-Q for the period ended June 30, 2002 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Henry Fong, Chief
Executive Officer and Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C.ss. 1350, as added by ss. 906 of the Sarbanes-Oxley Act of 2002,
that:

      A.   The Report fully complies with the requirements of Section 13(a) or
           15(d) of the Securities Exchange Act of 1934; and

      B.   The information contained in the Report fairly presents, in all
           material respects, the financial condition and results of operations
           of the Company as of and for the period covered by the Report.





                                      By: /s/ Henry Fong
                                      -----------------------------------
                                      Henry Fong
                                      Chief Executive Officer
                                      Chief Financial Officer
                                      August 14, 2002
#### ROCHESTER HOTEL CORP., Respondent, v. FOSTER & GLIDDEN ENGINEERING CO., Appellant.

(Supreme Court, Appellate Division, Fourth Department.

March 27, 1912.)

Action by the Rochester Hotel Corporation against the Foster & Glidden Engineering Company.

PER CURIAM.

Order, so far as appealed from, affirmed, with $10 costs and disbursements.

SPRING and KRUSE, JJ., dissent, and vote for modification by limiting the amount of costs imposed to the trial fee and disbursements of the trial, besides costs of the motion.
I 

109TH CONGRESS 

1ST SESSION H. R. 2406

To suspend temporarily the duty on Hexythiazox Technical. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 17, 2005

Mr. GRIJALVA introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL

To suspend temporarily the duty on Hexythiazox Technical.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. HEXYTHIAZOX TECHNICAL. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading:

‘‘ 9902.08.24 trans-5-(4-Chlorophenyl)-Ncyclohexyl-4-methyl-2-

oxothiazolidine-3-

carboxamide (Hexythiazox 

Technical) (CAS No. 

78587–05–0) (provided for 

in subheading 2934.10.90) .. Free No change No change On or before 

12/31/2009 ’’. 
2

•HR 2406 IH 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act.

Æ
##### 



Sarbanes-Oxley Act of 2002, Section 906
Certification of Chief Executive and Chief Financial Officers
  1.
    
    This Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities
Exchange Act of
1934, and2.
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and
results of operations of the Company.
 August 13, 2007
    By
    /s/ Norman L. LoweryNorman L. Lowery, Vice Chairman & CEOAugust 13, 2007
    By
    /s/ Michael A. CartyMichael A. Carty, Treasurer & CFO
I 

109TH CONGRESS 

1ST SESSION H. R. 2379 

To amend title 38, United States Code, to require the Department of Veterans 

Affairs to fill prescriptions for drugs and medicines written by private 

physicians. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 16, 2005 

Mr. LYNCH introduced the following bill; which was referred to the Committee 

on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to require the Department of Veterans Affairs to fill prescriptions for 

drugs and medicines written by private physicians. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Vets Rx Act of 2005’’. 
2 

•HR 2379 IH 

1 SEC. 2. DEPARTMENT OF VETERANS AFFAIRS PHARMACIES 

2 TO DISPENSE MEDICATIONS TO VETERANS 

3 ON PRESCRIPTIONS WRITTEN BY PRIVATE 

4 PRACTITIONERS. 

5 Section 1712 of title 38, United States Code, is 

6 amended by adding at the end the following new sub7 section: 

8 ‘‘(f)(1) The Secretary shall provide for Department 

9 health-care facilities to furnish to a veteran such drugs 

10 and medicines as may be ordered on prescription of a duly 

11 licensed physician in the treatment of any illness or injury 

12 of the veteran. 

13 ‘‘(2) The furnishing of drugs and medicines under 

14 this subsection shall be subject to the copayment require15 ment in section 1722A of this title.’’. 

Æ
EX-10.39




 STRICTLY CONFIDENTIAL 

EXHIBIT 10.39 

Employment Term Sheet 
 Set
forth below are the key management compensation terms of the proposed arrangements concerning the employment of Executive (as defined below) by EVERTEC GROUP, LLC (the “Company”) and is hereafter referred to as the
“Agreement.” 
  

			
	Name:		Frank G. D’Angelo (“Executive”).
		
	Position/Duties:		Interim President and Chief Executive Officer. Executive will report to the Board of Directors of the Company and will serve as a non-independent director of the Board of Directors. Executive will spend at least 2 weeks of every
month in Puerto Rico undertaking his duties as Interim President and CEO.
		
	Initial Term:		Executive’s initial term of employment will start on January 1, 2015 (the “Start Date”) and end on March 31, 2015 (the “Term”). At the end of the Term, Executive will re-join the Board of
Directors as its independent Chairman.
		
	Salary:		Executive’s base salary shall be $25,000 cash per month, payable in accordance with the Company’s standard payroll practices.
		
	Additional Benefits:		 Executive will be elegible for standard employee and executive benefits, which primarily consist of the following:

 
 Health Plan – to the extent Executive desires health insurance coverage (with
corresponding employee contribution depending on coverage)
  
 Company car – the
company will provide a company car plus related insurance or shall provide means of transaportation for the Executive during the Term.

		
	Restricted Stock Grant:		The Company will grant the Executive restricted stock units (“RSUs”) pursuant to the EVERTEC, Inc. 2013 Equity Incentive Plan equivalent to $75,000 in Company Common Stock on or about the Start Date, which grant
will vest on the day before the Company’s 2015 Annual Meeting of Stockholders or upon his earlier death or disability, provided that he is then providing service to the Company. On the vesting date, the RSUs will be converted to actual shares
and any accumulated dividend equivalent amounts since the date of grant will be delivered in cash.
		
	Reimbusement of Expenses:		Executive shall be entitled to the reimbursement of all reasonable and documented business-related expenses incurred by Executive during the Term, including, without limitation, any lodging and travel
expenses.










			
		
	Lodging:		Executive shall be entitled to the free use of a corporate apartment located in Condado, San Juan, Puerto Rico during the months of January and February 2015 or, in the alternative, may choose to stay at a hotel while providing
services in Puerto Rico during the Term.

 The parties have executed this Agreement as of December 17, 2014. 

 

									
	EXECUTIVE				EVERTEC GROUP, LLC
					
	By:		 /s/ Frank G. D’Angelo
				By:		 /s/ Arturo Díaz-Abramo

			Frank G. D’Angelo						Arturo Díaz-Abramo
									SVP Legal & Compliance
			
	Address:				Address:
							Road #176, Km 1.3
							Cupey Bajo, Rio Piedras Puerto Rico 00926
							P.O. Box 364527
							San Juan, Puerto Rico 00936-4527
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Molecular Plant Pathology Laboratory: Beltsville, MD
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Databases
                        Alfalfa Transcription Factor Database
                                    iPhyClassifier - Phytoplasma Sequence ClassificationSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Northeast Area Beltsville, Maryland (BARC) Beltsville Agricultural Research Center Molecular Plant Pathology Laboratory Docs







Viruses (Rose)headline bar */ARSUserFiles/80420560/virus_1.jpgOur study of plant viruses includes nucleotide sequencing of pathogenic isolates of the ilarvirus,*Prunus*necrotic ringspot virus*, and introduction of pathogen-derived resistance into cherry. We have also sequenced and are studying the genome expression of *Maize rayado fino virus*, the smallest plant virus known to replicate in both its insect vector and plant host. In addition, we have completed cloning and sequence analysis of two potyviruses - the GDD isolate of *Bean yellow mosaic virus* - and the first complete nucleotide sequence of *Beet mosaic virus*. Isolates of *Prunus necrotic ringspot virus* causing mild to severe symptoms cluster into phylogenetically distinct groups based on sequence analysis of the coat protein gene.abstract Sugar beet infected with *Beet mosaic virus*. abstract /ARSUserFiles/80420560/virus2.jpg


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
#### PEOPLE v. BANK OF STATEN ISLAND. In re MAYER.

(Supreme Court, Appellate Division. Third Department.

March 26, 1912.)

Proceeding by the People of the State of New York against the Bank of Staten Island. In the matter of the judicial settlement of the account of Joseph B. Mayer, as receiver of the Bank of. Staten Island. No opinion. Order reversed, without costs, and allowance fixed at §1,000. See, also, 132 N. Y. Supp. 1141.
EXHIBIT31

 

CERTIFICATION

 

I,Rosemary Williams, certify that:

 

-  I    have reviewed this  report on Form 10-KSB of Dogs International;Based    on my knowledge, this  report does not contain any untrue statement of    a material fact or omit to state a material fact necessary to make the    statements made, in light of the circumstances under which such statements    were made, not misleading with respect to the period covered by this     report;Based    on my knowledge, the financial statements, and other financial information    included in this  report, fairly present in all material respects the    financial condition, results of operations and cash flows of the small    business issuer as of, and for, the periods presented in this  report;	As the    small business issuer's only certifying officer, I am responsible for    establishing and maintaining disclosure controls and procedures (as defined    in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:-  Designed      such disclosure controls and procedures, or caused such disclosure      controls and procedures to be designed under my supervision, to ensure      that material information relating to the small business issuer, including      its consolidated subsidiaries, is made known to me by others within those      entities, particularly during the period in which this report is being      prepared;Evaluated      the effectiveness of the small business issuer's disclosure controls and      procedures and presented in this report my conclusions about the      effectiveness of the disclosure controls and procedures, as of the end of      the period covered by this report based on such evaluation; and		Disclosed in this report any change in the small business issuer's		internal control over financial reporting that occurred during the small		business issuer's most recent fiscal quarter (the small business		issuer's fourth fiscal quarter in the case of an  report) that has		materially affected, or is reasonably likely to materially affect, the		small business issuer's internal control over financial reporting; and    -  I    have disclosed, based on my most recent evaluation of internal control over    financial reporting, to the small business issuer's auditors and the audit	committee of the small    business issuer's board of directors (or persons performing the equivalent    functions):-  All      significant deficiencies and material weaknesses in the design or      operation of internal control over financial reporting which are      reasonably likely to adversely affect the small business issuer's ability      to record, process, summarize and report financial information; andAny      fraud, whether or not material, that involves management or other      employees who have a significant role in the small business issuer's      internal control over financial reporting.
 

Date:January 27, 2005

 

 

/s/RosemaryWilliams                            

RosemaryWilliams

Presidentand Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1998
<PERIOD-END>                               DEC-31-1997
<CASH>                                       1,323,314
<SECURITIES>                                         0
<RECEIVABLES>                               14,542,496
<ALLOWANCES>                                         0
<INVENTORY>                                  7,149,125
<CURRENT-ASSETS>                            25,639,249
<PP&E>                                       4,416,867
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              31,985,366
<CURRENT-LIABILITIES>                       21,474,224
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    10,989,942
<OTHER-SE>                                  (1,251,933)
<TOTAL-LIABILITY-AND-EQUITY>                31,985,366
<SALES>                                     23,125,471
<TOTAL-REVENUES>                            23,125,471
<CGS>                                       18,619,643
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             220,831
<INCOME-PRETAX>                                (62,628)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (62,628)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (62,628)
<EPS-PRIMARY>                                    (0.01)
<EPS-DILUTED>                                    (0.01)
        

</TABLE>